Skip to content

Amy W M Ewald

2 papers in the library · publishing 2014-2017

Papers

The C-2 derivatives of salvinorin A, ethoxymethyl ether Sal B and β-tetrahydropyran Sal B, have anti-cocaine properties with minimal side effects.

Psychopharmacology August 1, 2017 Amy W M Ewald, Peter J Bosch, Aimee Culverhouse et al.

Two novel analogues of salvinorin A, EOM Sal B and β-THP Sal B, were tested in rats for their ability to reduce cocaine-related behaviors and their side effects. EOM Sal B dose-dependently reduced drug-seeking behavior in a reinstatement model and, along with β-THP Sal B, attenuated cocaine-induced hyperactivity without affecting general locomotion. Neither compound produced anxiety-like or depressive-like effects in the elevated plus maze or forced swim tests. However, β-THP Sal B caused aversion in the conditioned place aversion test. EOM Sal B showed no effect on sucrose self-administration, indicating selectivity for cocaine-related behaviors. EOM Sal B was more potent than salvinorin A and β-THP Sal B with fewer side effects.

Salvinorin A analogs and other κ-opioid receptor compounds as treatments for cocaine abuse.

Advances in pharmacology (San Diego, Calif.) January 1, 2014 Bronwyn M Kivell, Amy W M Ewald, Thomas E Prisinzano

Salvinorin A, a compound from the plant Salvia divinorum, activates kappa-opioid receptors and reduces drug-seeking behaviors by regulating dopamine levels, similar to traditional kappa-opioid agonists but with fewer side effects like sedation and depression. However, its rapid metabolism limits clinical use. Newer analogs based on Salvinorin A's structure show improved pharmacokinetics and retain anti-addictive effects, offering promise for developing addiction treatments.